| CPC A61K 47/6803 (2017.08) [A61K 31/395 (2013.01); A61K 31/5383 (2013.01); A61K 31/5517 (2013.01); A61K 38/07 (2013.01); A61K 38/1729 (2013.01); A61K 47/542 (2017.08); A61K 47/545 (2017.08); A61K 47/55 (2017.08); A61K 47/65 (2017.08); A61K 47/68031 (2023.08); A61K 47/68035 (2023.08); A61K 47/6849 (2017.08); A61K 49/0052 (2013.01); A61K 49/0058 (2013.01); A61K 51/1093 (2013.01); A61P 31/04 (2018.01); A61P 35/00 (2018.01)] | 16 Claims |
|
1. A method of producing the compound of Formula (1B):
![]() wherein
BA is an antibody;
Gln is a glutamine residue of said BA;
SP is
![]() wherein subscripts u, w, x, and v are independently an integer from 1 to 20;
Z is
![]() wherein R′ is independently H, C1-3 alkyl, or two R′ together constitute a CHR, CHR—CHR, or O bridge;
R is independently at each occurrence H, C1-3 alkyl, —OC1-3 alkyl, or —NHC1-3 alkyl;
J is CH;
K is N;
L is
![]() D is a therapeutic moiety, wherein the therapeutic moiety is a maytansinoid, a tubulysin, an auristatin, a dolastatin, a camptothesin, a pyrrolobenzodiazepine, an antibiotic, an antiviral agent, an anti-inflammatory agent, an immunomodulator, an antifungal agent, a steroid, or D is an imaging agent moiety;
d is an integer from 1 to 2,
the method comprising the steps of:
a.) contacting: i) a compound having a structure according to Formula (V-x):
![]() wherein:
X is independently at each occurrence selected from
![]() I is an integer from 1 to 2;
with ii) a compound according to Formula (VI-y):
Y-L-D (VI-y);
wherein:
Y is a moiety according to
![]() to produce a compound having a structure according to Formula (V-x′z):
![]() b.) contacting the compound according to Formula (V-x′z) with a compound according to Formula (VI-y): Y-L-D (VI-y); and
c.) isolating the produced compound of Formula (1B).
|